Mage-A cancer/testis antigens inhibit p53 function by blocking its interaction with chromatin

Cancer Research

Volumn 70, Issue 24, 2010, Pages 10362-10370

  Marcar, Lynnette ^a   MacLaine, Nicola J ^b   Hupp, Ted R ^b   Meek, David W ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CANCER TESTIS ANTIGEN; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 2; OLIGONUCLEOTIDE; PROTEIN P53;

ARTICLE; CELL CYCLE ARREST; CELL DEATH; CHROMATIN; CONTROLLED STUDY; DRUG POTENCY; DRUG TARGETING; HUMAN; HUMAN CELL; INHIBITION KINETICS; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; TRANSCRIPTION REGULATION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ANTIGENS, NEOPLASM; BONE NEOPLASMS; CELL LINE, TUMOR; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; LUNG NEOPLASMS; OSTEOSARCOMA; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78650390294     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1341     Document Type: Article

References (37)

1. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008;9:402-12.
2. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007;8:275-83.
3. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 2009;137:413-31.
4. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 2009;9:862-73.
5. Meek DW. Tumour suppression by p53: a role for the DNA damage response?Nat Rev Cancer 2009;9:714-23.
6. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005;5:615-25.
7. Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T, Lucas S. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res 2001;61:5544-51.
8. Barker PA, Salehi A. The MAGE proteins: emerging roles in cell cycle progression, apoptosis, and neurogenetic disease. J Neurosci Res 2002;67:705-12. (Pubitemid 34226281)
9. Brasseur F, Rimoldi D, Lienard D, et al. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 1995;63:375-80.
10. Gure AO, Chua R, Williamson B, et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 2005;11:8055-62.
11. Kim J, Reber HA, Hines OJ, et al. The clinical significance of MAGEA3 expression in pancreatic cancer. Int J Cancer 2006;118:2269-75.
12. Ohman Forslund K, Nordqvist K. The melanoma antigen genes - any clues to their functions in normal tissues? Exp Cell Res 2001;265:185-94.
13. Yakirevich E, Sabo E, Lavie O, Mazareb S, Spagnoli GC, Resnick MB. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms. Clin Cancer Res 2003;9:6453-60.
14. Laduron S, Deplus R, Zhou S, et al. MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription. Nucleic Acids Res 2004;32:4340-50.
15. Monte M, Simonatto M, Peche LY, et al. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci USA 2006;103:11160-5. (Pubitemid 44156489)
16. Cronwright G, Le Blanc K, Gotherstrom C, Darcy P, Ehnman M, Brodin B. Cancer/testis antigen expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression. Cancer Res 2005;65:2207-15.
17. Cattoretti G, Rilke F, Andreola S, D'Amato L, Delia D. P53 expression in breast cancer. Int J Cancer 1988;41:178-83.
18. Russell A, Hendley J, Germain D. Inhibitory effect of p21 in MCF-7 cells is overcome by its coordinated stabilization with D-type cyclins. Oncogene 1999;18:6454-9.
19. Bartkova J, Bartek J, Vojtesek B, et al. Immunochemical analysis of the p53 oncoprotein in matched primary and metastatic human tumours. Eur J Cancer 1993;29A:881-6.
20. Picksley SM, Vojtesek B, Sparks A, Lane DP. Immunochemical analysis of the interaction of p53 with MDM2; fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 1994;9:2523-9.
21. Chen J, Marechal V, Levine AJ. Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 1993;13:4107-14. (Pubitemid 23187639)
22. Midgley CA, Fisher CJ, Bartek J, Vojtesek B, Lane D, Barnes DM. Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli. J Cell Sci 1992;101:183-9.
23. Patton JT, Mayo LD, Singhi AD, Gudkov AV, Stark GR, Jackson MW. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res 2006;66:3169-76.
24. Wilson IA, Niman HL, Houghten RA, Cherenson AR, Connolly ML, Lerner RA. The structure of an antigenic determinant in a protein. Cell 1984;37:767-78.
25. Roustan C, Benyamin Y, Boyer M, Cavadore JC. Structural variations in actins. A study of the immunological reactivity of the N-terminal region. Biochem J 1986;233:193-7.
26. Burke JR, Enghild JJ, Martin ME, et al. Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. Nat Med 1996;2:347-50.
27. Metivier R, Penot G, Hubner MR, et al. Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 2003;115:751-63.
28. Kaeser MD, Iggo RD. Chromatin immunoprecipitation analysis fails to support the latency model of regulation of p53 DNA binding activity in vivo. Proc Natl Acad Sci USA 2002;99:95-100.
29. Hupp TR, Meek DW, Midgley CA, Lane DP. Regulation of the specific DNA binding function of p53. Cell 1992;71:875-86.
30. Wallace M, Worrall E, Pettersson S, Hupp TR, Ball KL. Dual-site regulation of MDM2 E3-ubiquitin ligase activity. Mol Cell 2006;23:251-63.
31. Anderson CW, Appella E. Signaling to the p53 tumor suppressor through pathways activated by genotoxic and non-genotoxic stresses. In:Bradshaw RA, Dennis EA, editors. Handbook of Cell Signaling. Amsterdam: Elsevier; 2009. p. 237-47.
32. Meek DW, Anderson CW. Posttranslational modification of p53: cooperative integrators of function. Cold Spring Harb Perspect Biol 2009;1:a000950.
33. Espinosa JM, Emerson BM. Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol Cell 2001;8:57-69.
34. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W. Acetylation is indispensable for p53 activation. Cell 2008;133:612-26.
35. Lilyestrom W, Klein MG, Zhang R, Joachimiak A, Chen XS. Crystal structure of SV40 large T-antigen bound to p53: interplay between a viral oncoprotein and a cellular tumor suppressor. Genes Dev 2006;20:2373-82.
36. Espinosa JM. Mechanisms of regulatory diversity within the p53 transcriptional network. Oncogene 2008;27:4013-23.
37. Shaked H, Shiff I, Kott-Gutkowski M, Siegfried Z, Haupt Y, Simon I. Chromatin immunoprecipitation-on-chip reveals stress-dependent p53 occupancy in primary normal cells but not in established cell lines. Cancer Res 2008;68:9671-7.